Sponsored
From Overwhelmed to Empowered: Pluvicto is Changing Metastatic Prostate Cancer Care
July 30th 2025Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like wandering through a foggy wilderness, quiet and cautious, afraid that any sound might reveal vulnerability. When forced to rethink the direction of life and navigate the various treatment options available while bearing the emotional toll of the unknown, it would be understandable to feel overwhelmed. Knowing there’s a clear next step can offer hope, a reason to speak up, and a renewed sense of control. For many, that step could be Pluvicto® (lutetium Lu 177 vipivotide tetraxetan).
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Celebrating Life: Bob’s Experience with Follicular Lymphoma, a Slow-Growing, Indolent Cancer
January 30th 2024When Bob was first diagnosed and treated for follicular lymphoma, he refused to let the fear of the cancer returning dominate his life. Nearly 25 years later—after having experienced a relapse—Bob is still in remission and chooses to live his life to the fullest and celebrate life’s joys every day.